Joyce Kwan

Joyce Kwan

Auto-generated profile, based on publicly available information

Joyce Kwan

Harvard University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2024 in Science
Verified
Journal Article
Closed access
JKJoyce Kwan
Joyce Kwan
PSPerrin Segura
Perrin Segura
YLYanfei Li
Yanfei Li
SKSooshin Kim
Sooshin Kim
AGAlexey V. Gorshkov
Alexey V. Gorshkov
MGMarkus Greiner
Markus Greiner
Low-dimensional quantum systems can host anyons, particles with exchange statistics that are neither bosonic nor fermionic. However, the physics of anyons in one dimension remains largely unexplored. In this work, we realize Abelian anyons in one dimension with arbitrary exchange statistics using ultracold atoms in an optical lattice, where we engineer the statistical phase through a density-dependent Peierls phase. We explore the dynamical behavior of two anyons undergoing quantum walks and observe the anyonic Hanbury Brown–Twiss effect as well as the formation of bound states without on-site interactions. Once interactions are introduced, we observe spatially asymmetric transport in contrast to the symmetric dynamics of bosons and fermions. Our work forms the foundation for exploring the many-body behavior of one-dimensional anyons.

17 September 2025 in Physical Review Letters
Verified
Journal Article
Closed access
DMDaniel K. Mark
Daniel K. Mark
HHHong-Ye Hu
Hong-Ye Hu
JKJoyce Kwan
Joyce Kwan
CKChristian Kokail
Christian Kokail
SCSoonwon Choi
Soonwon Choi
SYSusanne F. Yelin
Susanne F. Yelin
Understanding the mechanism of high-temperature superconductivity is among the most important problems in physics, one for which quantum simulation can provide new insights. However, it remains challenging to characterize superconductivity in existing cold-atom quantum simulation platforms. Here, we introduce a protocol for measuring a broad class of observables in fermionic quantum gas microscopes, including long-range superconducting pairing correlations (after a repulsive-to-attractive mapping). The protocol only requires global controls followed by site-resolved particle number measurements-capabilities that have been already demonstrated in multiple experiments-and is designed by analyzing the Hilbert space of fermions on two sites. The protocol is sample-efficient and we further optimize our pulses for robustness to experimental imperfections such as lattice inhomogeneity. Our Letter introduces a general tool for manipulating quantum states on optical lattices, enhancing their ability to tackle problems such as high-temperature superconductivity.

14 April 2023 in Cancer Research
Verified
Journal Article
Closed access
FYFan Ye
Fan Ye
JHJianing Huang
Jianing Huang
SCSandra Chen
Sandra Chen
ELElla Li
Ella Li
JJJenny Jiang
Jenny Jiang
ZZZiyang Zhong
Ziyang Zhong
The tumor microenvironment (TME) has been identified as a significant obstacle to the success of immunotherapy, including anti-PD-1 therapy. The TME comprises several factors that limit the response rate to immunotherapy, including immunosuppressive cells such as regulatory T cells (Tregs), which directly or indirectly interact with effector cells and undermine the tumor recognition, activation, proliferation, and survival of the effector cells, thereby promoting tumor growth. To overcome suppressive TME, we designed AWT030, a first-in-class bi-functional IL-21 fusion protein that comprises a stability and potency optimized IL-21 mutein and an engineered functional domain that targets T cells. AWT030 is designed to selectively activate tumor-infiltrating CD8 T cells and suppress Tregs while avoiding the potential suppressive effect of IL-21 on dendritic cells.Compared to wild-type IL-21, mAWT030 greatly enhances the tolerability, half-life, and anti-tumor activity. In anti-PD-1 therapy resistant breast cancer EMT6 model, fibrosarcoma MCA205 model, and anti-PD-1 therapy responsive colon cancer MC38 model, mAWT030 achieved 100% complete response without noticeable toxicity, demonstrating a powerful synergy between tumor specific CD8 T cell activation axis and Treg suppression axis induced simultaneously by mAWT030. In addition, mAWT030 also exhibited a strong synergistic effect with anti-PD-1 antibody. Immunophenotyping revealed that AWT030 had minimal impact on circulating lymphocytes while altering the suppressive TME, with a significantly increased CD8 T cell population and suppressed Treg population. In summary, AWT030 is a novel bi-functional IL-21 fusion protein with high tumoral specificity, the excellent safety and antitumor activity of mAWT030 observed preclinically supports clinical development, focusing on treating PD-1 resistant/relapsed patients or combining with anti-PD-1 therapy. Citation Format: Fan Ye, Jianing Huang, Sandra Chen, Ella Li, Jenny Jiang, Hanna Lin, Michael Hua, Danny Huang, Zoey Huang, Joyce Kwan, Lili Cheng, Ziyang Zhong. AWT030: a first-in-class bi-functional IL-21 fusion protein selectively activates tumor infiltrated CD8 T cells and suppresses Treg cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB029.